71 results about "Bacterial polysaccharide" patented technology

The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to specific advantageous pnumococcal polysaccharide conjugates adjuvanted with 3D-MPL and substantially devoid aluminium-based adjuvant.

The invention relates to a bacterial polysaccharide-protein conjugate vaccine with immunogenicity, in particular to a conjugate vaccine which is formed by connecting a recombinant rotavirus protein with a bacterial polysaccharide by using a covalent bond, a nucleotide sequence for coding the recombinant rotavirus protein, a recombinant expression system, a protein expressed by the recombinant expression system, a preparation method of the conjugate vaccine and a pneumococcus polysaccharide-recombinant rotavirus protein conjugate vaccine. The bacterial polysaccharide is connected with a recombinant rotavirus surface protein through a covalent bond. The recombinant rotavirus protein is selected from a partial or complete amino acid sequence of a P-gene rotavirus protein and a partial or complete amino acid sequence of a G-gene rotavirus protein.

Process for the preparation of O-sulfated K4, K5 and K40 polysaccharides useful for the treatment of tumoral, HIV-1 and coagulation pathologies and in cosmetic preparations, wherein the K4, K5 or K40 polysaccharide in the form of sodium salt is suspended in an aprotic solvent and directly submitted to the reaction of O-sulfation with a pyridine-sulphur trioxide or trimetylamine-sulphur trioxide adduct or with chlorosulfonic acid.

The invention relates to novel, probiotic, anti-inflammatory strains of Bifidobacterium longum, their use for treatment of diseases, and for preparation of human or pet food or pharmaceutical compositions. The strains produce high amounts of exopolysaccharides with a high content of mannose- and glucose residues. Accordingly, the invention also relates to a bacterial polysaccharide composition obtained from the strains, their use for treatment of diseases, and pharmaceutical compositions comprising such polysaccharides.

The invention provides a multivalent immunogenic composition containing enterovirus antigens. The composition comprises inactivated EV71 antigens and/or inactivated CA16 antigens, and inactivated polio antigens. The composition can further comprise antigens selected from hepatitis A antigens, hepatitis B antigens, acellular pertussis antigens, tetanus toxoid, diphtheria toxoid, Haemophilus influenzae type b capsular polysaccharide, and meningococcal polysaccharide antigens, as well as physiologically acceptable carriers combined with bacterial polysaccharide antigens. The invention also provides a preparation method of the composition. The composition can prevent invasion of a plurality of pathogens simultaneously without interference among the antigens, and the immunogenicity is no less than that of individually activated antigens. With the composition, vaccination processes are significantly simplified, and the vaccination efficiency is improved with reduced costs.

Process for conjugation of bacterial saccharides including Streptococcus pneumoniae and Haemophilus influenzae saccharides by reductive amination are provided herein.

The invention discloses a purifying method of bacterial polysaccharide through Sepharose 4FF gel in the biological technical domain, which comprises the following steps: predisposing bacterial polysaccharide; purifying; collecting component before Kd0.5; obtaining high-purity and low-endotoxin product.

The invention discloses a bacterial polysaccharide protein conjugate vaccine using a hepatitis B surface antigen as carrier protein and a preparation method of the bacterial polysaccharide protein conjugate vaccine. According to the vaccine, protein is the hepatitis B surface antigen, and a bacterial polysaccharide is selected from any one or more of a haemophilus influenza type b polysaccharide, group A, group C, group Y and group W135 meningococcal polysaccharides, a salmonella typhi type Vi polysaccharide, a group B streptococcus type Ia polysaccharide and the like, pneumococcus serotype type 1, 2 and the like, and salmonella paratyphi type A or salmonella paratyphi type B. Animal experiments show that the antibody positive conversion rates of the bacterial polysaccharide and the hepatitis B surface antigen in the vaccine are both more than 85%, so that the vaccine is relatively high in antibody positive conversion rate; carrier protein plays a role in transforming the bacterial polysaccharide from a T-cell-independent antigen into a T-cell-dependent antigen, and also can be used for preventing diseases caused by hepatitis B virus; and by adopting the bacterial polysaccharide protein conjugate vaccine disclosed by the invention, the problem of performing immunization inoculation on infants and young children under 2 years old can be solved, the function of one injection with multiple immune effects also can be achieved, and the use crowd and coverage rate of the vaccine can be expanded.

A method of collecting, sterilizing, standardizing, drying and mixing rumen fluid while retaining the activity of the contained bacterial polysaccharides is described. Nutritional compositions including the resulting product, probiotics, nutricines, vitamins, minerals, an amino acid, and a monosaccharide are depicted. The use of this resulting nutritional composition the first few days of young animals' lives result in decreased diarrhea morbidity, severity and mortality. It also helps supply nutrients for the support of natural immune response and function.

The present invention relates to the field of combined vaccine compositions which are effective against all forms of meningococcal diseases as well as typhoid fever. The vaccine formulations comprising antigens from capsular polysaccharides of Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis Y, Neisseria meningitidis W135, Neisseria meningitidis X, Salmonella typhi Vi capsular polysaccharide (ViPs) or capsular ViPs conjugated to a carrier protein tetanus toxoid (ViPs-TT). This invention is also related to improved methods, especially the use of an improved feed media and an improved method of downstream processing and industrial purification of capsular polysaccharides. The vaccine is free of any animal component or alcohol and is in absolute compliance with respect to the religious sentiments of various ethnic groups. The composition is highly effective and stable, yet cost-effective and affordable, especially for lower-middle income and low-income countries.

The invention relates to the field of biology, in particular to application of an aminopeptidase reducing function in precaution and/or prevention of thallus biofilm formation, promotion of biofilm degradation and PslG release, reduction of the thallus content in a biofilm and improvement of antibiotic sensibility of thalli and application of an aminopeptidase reducing function method in preparation of drugs for precaution and/or prevention of thallus biofilm formation, promotion of biofilm degradation and PslG release, reduction of the thallus content in a biofilm and improvement of antibiotic sensibility of thalli. By adopting the aminopeptidase reducing function, lots of thalli in the biofilm are dead due to nutrition deficiency, dead bacteria release Psl polysaccharide hydrolase, hydrolysis of exopolysaccharides in the biofilm is promoted, and finally biofilm disruption is caused. Therefore, by developing drugs for aminopeptidase, biofilm disruption is promoted, the drug resistanceof biofilm thalli is reduced, and finally the purpose of removing harmful bacterium biofilms with antibiotics is achieved.

The invention discloses a biological preparation method of typhoid glycoprotein and an application thereof. The invention discloses a method for preparing bacteria polysaccharide-modified protein, a substrate protein of neisseria meningitidis O-oligosaccharyltransferase PglL and the neisseria meningitidis O-oligosaccharyltransferase PgIL are co-expressed in a bacteria defective in O-antigen ligase genes, and the bacteria polysaccharide-modified protein is obtained. The biological preparation method has wide application prospect for increasing uniformity of vaccine, increasing the production efficiency of the vaccine, and reducing cost; and the vaccine can be used for preventing the diseases caused by typhoid pathogen.

The invention provides a culture method for improving yield and viscosity of bacterial polysaccharides. By using the characteristic that penbritin can be simultaneously used as a mutagenic agent and bacterial cell wall peptidoglycan to synthesize stress factors, the penbritin is added to subsequent subculture processes of bacterial isolates for producing different polysaccharides; the adding amount of the penbritin is gradually increased along with an increase of passage number, so as to improve thrill on bacterial cells; and a series of high-producing strains with different viscosities and improvement degrees can be screened in the continuous passage process, so as to adapt to different application requirements. Therefore, the production cost is reduced.